The publication “NLRP3 regulates epithelial barrier integrity and protects from airway hyperresponsiveness in experimental allergic asthma” is the result of close, cross-site collaboration within the German research landscape. Researchers from the DZL sites in Hannover and Munich worked together with the associated DZL site in Berlin and the newly established German Center for Child and Adolescent Health. The project was funded by the CHAMP consortium (CHildhood Allergy and tolerance: Biomarkers and Predictors) with support from the BMFTR.

Using an experimental model of allergic asthma, the authors investigated the consequences of genetic NLRP3 deficiency. NLRP3-deficient animals showed markedly increased airway hyperresponsiveness and enhanced mucus production. These functional changes were accompanied by a clear structural weakening of the epithelial barrier. Key components of cell–cell junctions in the bronchial epithelium, including tight junction and adhesion proteins, were significantly reduced. As a result, epithelial permeability increased, facilitating immune contact with inhaled allergens and further amplifying asthmatic inflammation.

Notably, these effects were not limited to the animal model. Pharmacological inhibition of NLRP3 in human bronchial epithelial cells also led to reduced expression of key barrier proteins. This directly links experimental basic research with human-relevant mechanisms. “Our findings show that NLRP3 is not only a classical immune sensor but also plays a fundamental role in maintaining airway epithelial barrier integrity,” emphasises first author Dr Stephanie DeStefano. “Especially in allergic asthma, this opens a new perspective on disease mechanisms that have so far been viewed primarily from an immunological standpoint.”

The particular strength of the study lies in this functional re-evaluation of NLRP3. While earlier work mainly focused on its role in activating inflammatory cascades, this publication brings the structural stability of the airway epithelium to the forefront. The data suggest that NLRP3 acts as a kind of molecular guardian, preserving barrier function and protecting against excessive airway reactivity. Importantly, NLRP3 should not be understood as a therapeutic target per se, but rather as a central component of a finely balanced system between barrier maintenance and immune response.

This shift in perspective has far-reaching implications for translational research. “The study expands our understanding of NLRP3 beyond its role in immune responses,” explains last author Gesine Hansen, Director of the Department of Paediatric Pneumology, Neonatology and Allergology at Hannover Medical School. “It highlights how closely barrier function and immunological regulation in the airways are connected – an aspect that is highly relevant for future therapeutic strategies.” In particular, the findings open new avenues for asthma research with regard to early disease mechanisms and age-related differences in allergic airway disorders.

Original publication:

DeStefano S, Grychtol R, Funken D, Habener A, Tamm S, Stanke F, Greiner W, Beyer K, Hamelmann E, Kabesch M, von Mutius E, Schaub B, Jirmo AC, Hansen G; CHAMP study group. NLRP3 regulates epithelial barrier integrity and protects from airway hyperresponsiveness in experimental allergic asthma. Front Immunol. 2025 Nov 27;16:1655205. doi: 10.3389/fimmu.2025.1655205. PMID: 41394833; PMCID: PMC12695735.

Text: BREATH/AB

Photo: privat